MIRUM PHARMACEUTICALS, INC.

(MIRM)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
25.58 USD   +5.66%
05/18Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
05/10Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
05/05MIRUM PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of therapies for rare and orphan diseases. The Company's main focus is the development and commercialization of LIVMARLI (maralixibat) oral solution (Livmarli) and Volixibat. Its pipeline consists of rare pediatric indications for Livmarli and orphan adult indications for its second product candidate, Volixibat. Livmarli is an oral solution as a once-daily medicine for cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. Volixibat, is an oral, minimally absorbed agent designed to inhibit ileal bile acid transporter (IBAT), for the treatment of adult patients with cholestatic liver diseases. The Company is developing volixibat for the treatment of intrahepatic cholestasis of pregnancy (ICP), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC).

Number of employees : 137 people.
Sales per Business
20202021Delta
Novel Therapies--19.14100%-
USD in Million
Sales per region
20202021Delta
United States--19.14100%-
USD in Million
Managers
Name Title Age Since
Christopher Peetz President, Chief Executive Officer & Director 42 2019
Ian Clements, Dr. Chief Financial Officer 52 2020
Pamela Vig, Dr. Head-Research & Development 50 2021
Peter Radovich Chief Operating Officer 43 2020
Paul K. Ross Chief Compliance Officer - 2020
Lara Krupka-Longpre Chief Development Officer 51 2018
Erin Campany Senior Vice President-Human Resources 54 2022
Members of the board
Name Title Age Since
Michael G. Grey Chairman 68 2020
Edward Mathers Independent Director 61 2018
Patrick J. Heron Independent Director 50 2018
Niall O'Donnell, Dr. Independent Director 48 2018
Laurent Fischer, Dr. Independent Director 57 2019
Laura A. Brege Independent Director 63 2019
Carol L. Brosgart, Dr. Independent Director 69 2021
William C. Fairey Independent Director 56 2021
Christopher Peetz President, Chief Executive Officer & Director 42 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 31,924,435 30,348,519 95.1% 89,066 0.3% 95.1%
Shareholders
NameEquities%
NEA Management Co. LLC 4,187,801 13.2%
Frazier Management LLC 3,566,912 11.2%
Deerfield Management Company LP 3,282,912 10.3%
Novo Holdings A/S (Investment Company) 2,200,000 6.93%
RiverVest Venture Management LLC 1,921,118 6.05%
Rock Springs Capital Management LP 1,538,814 4.85%
AXA Investment Managers UK Ltd. 992,555 3.13%
The Vanguard Group, Inc. 796,869 2.51%
Polar Capital LLP 769,425 2.42%
Baker Bros. Advisors LP 647,313 2.04%
Company contact information
Mirum Pharmaceuticals, Inc.
950 Tower Lane
Suite 1050
Foster City, CA 94404

Phone : +1.650.667.4085
Web : http://www.mirumpharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Mirum Pharmaceuticals, Inc.